ArticleMicroorganisms2021
A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation.
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Factors affecting voriconazole pharmacokinetic variability in critically ill patients: a systematic review.Critical care (London, England) · 2025Pooled it
- Guideline
- Time-varying voriconazole clearance during extracorporeal membrane oxygenation.Antimicrobial agents and chemotherapy · 2026Observational
- Invasive Fungal Infections During Extracorporeal Membrane Oxygenation: A Case Series from Intensive Care Unit and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Antimicrobial pharmacokinetics and stewardship in critically Ill adult patients receiving ECMO: Challenges, evidence, and future directions.JHLT open · 2026Article
- Effects of Extracorporeal Membrane Oxygenation Circuits on Drug Sequestration: A Review of Ex Vivo Experiments.Journal of clinical medicine · 2025Review
- Optimizing Drug Therapy in ECMO-Supported Critically Ill Adults: A Narrative Review and Clinical Guide.Pharmacy (Basel, Switzerland) · 2025Review
- A narrative review on antimicrobial dosing in adult critically ill patients on extracorporeal membrane oxygenation.Critical care (London, England) · 2024Review
- Renal Replacement Therapy as a New Indicator of Voriconazole Clearance in a Population Pharmacokinetic Analysis of Critically Ill Patients.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Factors influencing voriconazole plasma level in intensive care patients.JAC-antimicrobial resistance · 2024Article
- Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation.Clinical pharmacokinetics · 2023Review
- Voriconazole Pharmacokinetics in Critically Ill Patients and Extracorporeal Membrane Oxygenation Support: A Retrospective Comparative Case-Control Study.Antibiotics (Basel, Switzerland) · 2023Article
- Invasive Pulmonary Aspergillosis in Coronavirus Disease 2019 Patients Lights and Shadows in the Current Landscape.Advances in respiratory medicine · 2023Review
- Multidrug Resistance in Critically Ill Patients: An Unresolved Issue.Microorganisms · 2023Article
- Adequate Antimicrobial Dosing in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: Where to Go from Here?American journal of respiratory and critical care medicine · 2023Article
- The Influence of Extracorporeal Membrane Oxygenation on Antibiotic Pharmacokinetics.Antibiotics (Basel, Switzerland) · 2023Review
- Antimicrobial Exposure in Critically Ill Patients with Sepsis-Associated Multi-Organ Dysfunction Requiring Extracorporeal Organ Support: A Narrative Review.Microorganisms · 2023Review
- The impact of extracorporeal membrane oxygenation on the exposure to isavuconazole: a plea for thorough pharmacokinetic evaluation.Critical care (London, England) · 2022Article
- Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients.Journal of fungi (Basel, Switzerland) · 2022Review
- Antibiotics and ECMO in the Adult Population-Persistent Challenges and Practical Guides.Antibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVoriconazole is one of the first-line therapies for invasive pulmonary aspergillosis. Drug concentrations might be significantly influenced by the use of extracorporeal membrane oxygenation (ECMO). We aimed to assess the effect of ECMO on voriconazole exposure in a large patient population.
methodsCritically ill patients from eight centers in four countries treated with voriconazole during ECMO support were included in this retrospective study. Voriconazole concentrations were collected in a period on ECMO and before/after ECMO treatment. Multivariate analyses were performed to evaluate the effect of ECMO on voriconazole exposure and to assess the impact of possible saturation of the circuit's binding sites over time.
resultsSixty-nine patients and 337 samples (190 during and 147 before/after ECMO) were analyzed. Subtherapeutic concentrations (<2 mg/L) were observed in 56% of the samples during ECMO and 39% without ECMO (
conclusionsNo significant ECMO-effect was observed on voriconazole exposure. A large proportion of patients had voriconazole subtherapeutic concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.